• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Integer Holdings Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    10/24/25 8:01:29 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ITGR alert in real time by email
    Form 8-K
    False 0001114483 0001114483 2025-10-23 2025-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________

    FORM 8-K

    _________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):  October 23, 2025

    _______________________________

    INTEGER HOLDINGS CORPORATION

    (Exact name of registrant as specified in its charter)

    _______________________________

    Delaware 1-16137 16-1531026
    (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

    5830 Granite Parkway, Suite 1150

    Plano, Texas 75024

    (Address of Principal Executive Offices) (Zip Code)

    (214) 618-5243

    (Registrant's telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

    _______________________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.001 par value per share ITGR New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     
     
    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On October 23, 2025, the Board of Directors (the “Board”) of Integer Holdings Corporation (the “Company”) appointed Payman Khales as a member of the Board, effective October 24, 2025, in connection with the previously disclosed transition plan where Mr. Khales was appointed as the Company’s President and Chief Executive Officer (“CEO”), also effective October 24, 2025. Mr. Khales will serve on the Company’s Technology Strategy Committee. Mr. Khales’ term as director will continue until the next annual meeting of stockholders and until his successor is elected and qualified or until his earlier death, resignation or removal.

     

    Mr. Khales will succeed Joseph W. Dziedzic, the CEO and director of the Company. As previously disclosed, also effective October 24, 2025, Mr. Dziedzic will serve as a Special Advisor for the Company until March 31, 2026, to assist Mr. Khales with transition matters.

     

    In connection with Mr. Khales’ appointment as CEO, on October 23, 2025, the Company entered into an Employment Agreement with Mr. Khales (the “Employment Agreement”). The Employment Agreement is intended to supersede and replace (1) the Offer Letter, dated as of February 6, 2018, between the Company and Mr. Khales and (2) the Change of Control Agreement, dated February 20, 2018, between the Company and Mr. Khales. Under the Employment Agreement, Mr. Khales will be entitled to the compensation and benefits described below.

     

    Base Salary

     

      • An annual base salary rate of $875,000, which will be reviewed for increase at least annually.

     

    Annual Short-Term Cash Incentive Bonus

     

      • During his service as CEO, Mr. Khales will be eligible for an annual cash short-term incentive award (the “Annual STI Bonus”), with a target Annual STI Bonus opportunity equal to 100% of his base salary actually earned for such fiscal year (“Target STI Bonus”) based on performance metrics and relative weighting established by the Board (or an applicable committee of the Board).

     

      • For fiscal year 2025, Mr. Khales Annual STI Bonus will be calculated based on actual performance, but based on a mix of (1) his eligible earnings during fiscal year 2025 while he served as Chief Operating Officer of the Company and the goals and target Annual STI Bonus set by the Board for his service as Chief Operating Officer in fiscal year 2025 and (2) his eligible earnings during fiscal year 2025 while serving as CEO and the goals and target Annual STI Bonus set by the Board for his service as CEO in fiscal year 2025.

     

    Long-Term Incentives

     

      • During his service as CEO, Mr. Khales will be eligible to participate in the Company’s annual long-term incentive compensation programs as may generally be in effect from time to time for all U.S. executives at the level of Executive Vice President and above at the Company.

     

      • In 2026, Mr. Khales’ aggregate annual long-term incentive award target will not be less than $5,000,000.

     

    Special Equity Grant

     

      • In connection with his promotion, Mr. Khales will receive a special grant of service-based restricted stock units under the Integer Holdings Corporation 2021 Omnibus Incentive Plan (the “Incentive Plan”) with (1) a grant date of October 24, 2025 (the “Grant Date”), (2) a grant date fair value equal to $550,000, (3) ratable annual vesting over a three-year period from the Grant Date, with the first ratable portion vesting on the first anniversary of the Grant Date, and (4) other terms and conditions provided for in the Incentive Plan and the standard Company award agreement for substantially similar awards.

     

    Other Benefits

     

      • The Company will provide and maintain, at the Company’s sole reasonable expense, term life insurance with a total face value of not less than $5,000,000 (or such lesser maximum amount of coverage that the Company can reasonably obtain) on the life of Mr. Khales.

     

      • Mr. Khales will be eligible to participate in the executive class long-term disability insurance program as may generally be in effect from time to time for all U.S. executives at the level of Executive Vice President and above at the Company.

     

      • The Company will provide to Mr. Khales, at the Company’s sole reasonable expense, an annual comprehensive physical exam, generally as provided for under the Company’s Key Management Physical Examination Program (or any successor or reasonably-comparable Company program).

     

      • Mr. Khales will be eligible to participate in the employee benefit plans, programs, and policies (including group term life insurance coverage and paid time off programs), as may generally be in effect from time to time for all U.S. executives at the level of Executive Vice President and above at the Company.

     

      • Mr. Khales will receive reimbursement for all reasonable expenses incurred by him in the performance of his duties as CEO.

     

      • Mr. Khales will receive reimbursement for up to $20,000 in legal expenses incurred in the preparation and negotiation of the terms of the Employment Agreement.

     

    Non-Change in Control Severance Compensation

     

    Under the Employment Agreement, for an involuntary termination without cause or for good reason (each as described in the Employment Agreement, collectively, a “Qualifying Termination”) not in connection with a change in control, Mr. Khales will receive (the “Pre-CIC Severance Benefits”):

     

      • (1) Earned but unpaid base salary through the date of the Qualifying Termination, (2) unreimbursed but reimbursable expenses, and (3) payment of his unpaid Annual STI Bonus for the fiscal year immediately preceding the fiscal year in which the Qualifying Termination occurs (collectively, the “Accrued Obligations”);

     

      • Cash severance equal to two times the sum of (1) Mr. Khales’ annual base salary rate plus (2) his Target STI Bonus;

     

      • A lump sum payment equal to the product of (1) 110% of the monthly premium (or the equivalent cost of coverage for self-insured benefits) for medical and prescription drug coverage for the most recently completed month of medical and prescription drug coverage for Mr. Khales and his spouse and any dependent children who were covered under the Company’s medical and prescription drug plans immediately prior his Qualifying Termination, times (2) 24; and

     

      • Any other benefits owed to Mr. Khales under any plan, policy, practice or program of, or any other contract or agreement with, the Company to which he is entitled (collectively, the “Other Benefits”);

     

    In addition, (1) each of Mr. Khales' performance-based equity awards then held (and outstanding for at least one year) will vest on a pro-rated basis regarding actual performance and his term of employment during the applicable performance period (performance-based equity awards then held for less than one year will be forfeited), (2) each of Mr. Khales' time-based equity awards granted on or after October 24, 2025 and then held will vest on a pro-rated basis regarding his term of employment during the applicable vesting period (or will vest according to the applicable award agreement, if the award agreement for such time-based equity award provides for more favorable treatment), and (3) each of Mr. Khales' time-based equity awards granted prior to October 24, 2025 will be governed by the applicable award agreement.

     

    Severance Compensation following a Change in Control

     

    Under the Employment Agreement, for a Qualifying Termination occurring in the period starting 60 days prior to a change in control and ending 24 months following, Mr. Khales will receive (the “CIC Severance Benefits”):

     

      • The Pre-CIC Severance Benefits;

     

      • A lump sum payment equal to two times the Company’s total contributions for Mr. Khales to any retirement plan (whether qualified or nonqualified) of the Company in effect on the date of the Qualifying Termination, for the plan year preceding the date of the Qualifying Termination;

     

      • If the Company has not granted any annual long-term incentive awards to Mr. Khales for the fiscal year that includes the date of the Qualifying Termination, a lump sum payment in cash equal to the product obtained by multiplying (1) the aggregate grant date fair value of any annual long-term incentive awards granted by the Company to Mr. Khales for the immediately preceding fiscal year, times (2) a fraction, the numerator of which is the number of full months Mr. Khales was employed by the Company during the fiscal year that includes the date of the Qualifying Termination, and the denominator of which is 36;

     

      • Up to $25,000 for executive outplacement services utilized by Mr. Khales;

     

      • If, within the 18-month month period immediately preceding the date of the Qualifying Termination, Mr. Khales had relocated his primary residence from one location to the location on the date of the Qualifying Termination at the request of the Company, then the Company will reimburse Mr. Khales in cash for any relocation expenses actually incurred in the 12 months immediately following the Qualifying Termination by Mr. Khales in moving his primary residence to any location within 35 miles of the original location; and

     

      • Mr. Khales will remain eligible for a prorated Annual STI Bonus for the fiscal year that includes date of the Qualifying Termination.

     

    In addition, for each outstanding performance-based equity award then held by Mr. Khales such performance-based equity award will vest and become non-forfeitable based on the full (i.e. not prorated) award opportunity and earned based on one or more levels of performance for such performance-based equity award as specifically determined in writing by the Compensation and Organization Committee of the Board reasonably prior to the change in control, and such award will be settled in accordance with the applicable award agreement. For each time-based equity award then held by Mr. Khales such time-based equity award, to the extent not previously vested, will vest and become non-forfeitable, and such award will be settled in accordance with the applicable award agreement.

     

    Mr. Khales will also receive the Accrued Obligations and Other Benefits described above for a voluntary termination without good reason or termination due to death or disability. The Employment Agreement also provides for payments otherwise due upon a change in control to be reduced to ensure that none are subject to the golden parachute excise tax (or full payment subject to the excise tax, depending on which approach puts Mr. Khales in the best after-tax position). Other than for the Accrued Benefits and Other Benefits described above, payment of the Pre-CIC Severance Benefits or CIC Severance Benefits are subject to Mr. Khales’ timely execution and non-revocation of a release of claims in favor of the Company, as further described in the Employment Agreement, plus application of the Company’s compensation clawback policy, as applicable. During his employment, Mr. Khales will not receive any additional compensation for his service on the Board.

     

    Item 7.01. Regulation FD Disclosure.

     

    On October 24, 2025, the Company issued a press release announcing the completion of the CEO transition plan. A copy of the release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific references in such a filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description of Exhibit
         
    99.1   Press Release dated October 24, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      INTEGER HOLDINGS CORPORATION
         
       
    Date: October 24, 2025 By:  /s/ Lindsay K. Blackwood        
        Lindsay K. Blackwood
        Senior Vice President, General Counsel and Corporate Secretary
       

     

    Get the next $ITGR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ITGR

    DatePrice TargetRatingAnalyst
    10/24/2025Buy → Hold
    Argus
    10/24/2025$80.00Overweight → Equal Weight
    Wells Fargo
    10/24/2025$77.00Buy → Neutral
    Citigroup
    10/24/2025$87.00Buy → Neutral
    BofA Securities
    10/24/2025Buy → Hold
    The Benchmark Company
    5/22/2025$140.00Neutral → Buy
    Citigroup
    3/28/2025$145.00Outperform
    Raymond James
    2/21/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ITGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Integer Holdings Corporation Board Authorizes $200 Million Share Repurchase Program

    PLANO, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that its Board of Directors has authorized a share repurchase program of up to $200 million of the Company's outstanding common stock. "This share repurchase program reflects the confidence of the Board and management in our strategy, financial position, and ability to generate strong free cash flows," said Payman Khales, Integer's president and CEO. The Company intends to primarily utilize cash on hand and free cash flows to fund the share repurchase program. The timing and volume of share repurchases may

    11/4/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Payman Khales Assumes Role as Integer President and CEO

    ~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company's Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as Preside

    10/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation Reports Third Quarter 2025 Results

    ~ Continued strong sales and profit growth in 3Q25 ~~ Updating 2025 sales and profit outlook; providing preliminary outlooks for 2026 and 2027 ~ PLANO, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended September 26, 2025. Third Quarter 2025 Highlights (compared to Third Quarter 2024, except as noted) Sales increased 8% to $468 million, with organic growth of 7%.GAAP operating income decreased $2 million to $56 million, a decrease of 3%. Non-GAAP adjusted operating income increased $10 million to $86 million, an increase of 14%.GAAP income from continuing operations increased $3 million to $40 million, an

    10/23/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Financial Officer Smith Diron bought $74,967 worth of shares (1,116 units at $67.19), increasing direct ownership by 17% to 7,698 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:19:02 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Capps Cheryl C bought $106,720 worth of shares (1,600 units at $66.70), increasing direct ownership by 16% to 11,702 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:16:21 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    President & CEO Khales Payman bought $203,067 worth of shares (3,127 units at $64.94), increasing direct ownership by 16% to 22,865 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    10/30/25 4:05:07 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    SEC Filings

    View All

    $ITGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Integer Holdings Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Integer Holdings Corp (0001114483) (Filer)

    11/4/25 8:01:46 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Integer Holdings Corp (0001114483) (Filer)

    10/24/25 8:01:29 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form 10-Q/A filed by Integer Holdings Corporation

    10-Q/A - Integer Holdings Corp (0001114483) (Filer)

    10/24/25 7:36:36 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Chief Financial Officer Smith Diron bought $74,967 worth of shares (1,116 units at $67.19), increasing direct ownership by 17% to 7,698 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:19:02 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Capps Cheryl C bought $106,720 worth of shares (1,600 units at $66.70), increasing direct ownership by 16% to 11,702 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:16:21 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    President & CEO Khales Payman bought $203,067 worth of shares (3,127 units at $64.94), increasing direct ownership by 16% to 22,865 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    10/30/25 4:05:07 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Integer Holdings downgraded by Argus

    Argus downgraded Integer Holdings from Buy to Hold

    10/24/25 2:15:30 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Integer Holdings from Overweight to Equal Weight and set a new price target of $80.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Citigroup with a new price target

    Citigroup downgraded Integer Holdings from Buy to Neutral and set a new price target of $77.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Leadership Updates

    Live Leadership Updates

    View All

    Payman Khales Assumes Role as Integer President and CEO

    ~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company's Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as Preside

    10/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Appoints Michael Coyle to Board of Directors

    ~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Bef

    7/10/25 4:52:01 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

    SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

    12/7/22 4:05:00 PM ET
    $EAR
    $ITGR
    $VAPO
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $ITGR
    Financials

    Live finance-specific insights

    View All

    Integer Holdings Corporation Reports Third Quarter 2025 Results

    ~ Continued strong sales and profit growth in 3Q25 ~~ Updating 2025 sales and profit outlook; providing preliminary outlooks for 2026 and 2027 ~ PLANO, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended September 26, 2025. Third Quarter 2025 Highlights (compared to Third Quarter 2024, except as noted) Sales increased 8% to $468 million, with organic growth of 7%.GAAP operating income decreased $2 million to $56 million, a decrease of 3%. Non-GAAP adjusted operating income increased $10 million to $86 million, an increase of 14%.GAAP income from continuing operations increased $3 million to $40 million, an

    10/23/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Announces Conference Call to Discuss Third Quarter 2025 Results

    PLANO, Texas, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the third quarter ended Sept. 26, 2025, on Thursday, Oct. 23, 2025, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the third quarter on Oct. 23 prior to the conference call. Conference call details: Date: Thursday, Oct. 23, 2025Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 307-1963Conference ID: 3

    9/25/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation Reports Second Quarter 2025 Results

    ~ Continued strong sales and profit growth in 2Q25 ~ ~ Raising 2025 full year adjusted operating income and EPS outlook midpoint ~ PLANO, Texas, July 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended June 27, 2025. Second Quarter 2025 Highlights (compared to Second Quarter 2024, except as noted) Sales increased 11% to $476 million, with organic growth of 11%.GAAP operating income increased $5 million to $59 million, an increase of 9%. Non-GAAP adjusted operating income increased $10 million to $81 million, an increase of 15%.GAAP income from continuing operations increased $6 million to $37 m

    7/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/9/24 9:59:01 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    1/30/24 1:15:44 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/10/23 2:42:23 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care